Ever Supreme Bio Technology Co. Ltd. announces submission of a Phase a IND for UMSC01 in patients with Acute Myocardial Infarction to Taiwan FDA. Date of occurrence of the event: January 9, 2023.

New drug name or code: Allogeneic umbilical cord mesenchymal stem cells(UMSC01). Indication: For the treatment of Acute Myocardial Infarction. Planned development stages: Phase a IND/Phase b IND/Phase IND /New Drug Application (NDA).Current development stage: Application submission/approval/disapproval/each of clinical trials (include interim analysis):Submitted a phase a IND application of UMSC01 for the treatment of patients with Acute Myocardial Infarction to Taiwan FDA.

If not approved by competent authority, or should the interim analysis or the clinical trial not reach statistical significance, the risks and the associated measures the Company may occur: N/A. After obtaining official approval or the results of interim analysis or the clinical trial reaching statistical significance, the future strategy will be: N/A. Accumulated investment expenditure incurred: Undisclosed .Upcoming development plan: Estimated date of completion: Depends on the review time of Taiwan FDA. Estimated responsibilities: Authorization fees, research and development costs and administrative fees. Market situation: According to Global Data data, the number of people suffering from acute myocardial infarction worldwide is expected to reach 30.62 million, with a compound annual growth rate (CAGR) of 2.03% from 2015 to 2025, showing that the myocardial Infarction treatment market demand continues to grow up.